At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings
In Brief
A Phase 3 clinical trial evaluating Paxlovid and Antioxidant for COVID-19. Active but no longer recruiting, targeting 797 participants across 6 sites.
Detailed Summary
CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.
Study Details
Timeline
Interventions
This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)